Loading...
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
Lepage, C Dahan, L Bouarioua, N Toumpanakis, C Legoux, J Le Malicot, K Guimbaud, R Smith, D Tougeron, D Lievre, A
Lepage, C
Dahan, L
Bouarioua, N
Toumpanakis, C
Legoux, J
Le Malicot, K
Guimbaud, R
Smith, D
Tougeron, D
Lievre, A
Citations
Altmetric:
Abstract
Patients with metastatic or locally advanced, non-resectable, grade 1 or 2 well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Patients (Pts) with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.
Description
Date
2017-03-11
Publisher
Collections
Keywords
Type
Article
Citation
Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. 2017, 49(5):568-571 Dig Liver Dis